Drugs / 18F-deoxyglucose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00576563 | Mar 2007 → Jan 2015 | rectal cancer | Maastricht Radiation Oncology | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-deoxyglucose | “To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after...” NCT00576563 ↗ |
| Known as | FDG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00576563 ↗ |
| Modality | Diagnostic / imaging agent | “Repetitive FDG-PET-CT scans in order to assess early tumour response monitoring.” NCT00576563 ↗ |